Pricing Log in Create free account

BioCardia, Inc. (BCDA) vs Lipocine Inc. (LPCN)

BioCardia, Inc. and Lipocine Inc. are both Biotechnology companies. BioCardia, Inc. and Lipocine Inc. are of similar size ($13.5M and $12.6M). BioCardia, Inc. grew revenue faster over the last twelve months: 0.71% against −13.4%. BioCardia, Inc. has the higher net margin (0.00% vs −249.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Lipocine Inc. leads on 8 and BioCardia, Inc. on 7.

Valuation

Metric BCDA LPCN Biotechnology median
P/E n/m n/m 10.60
P/S 24.58 3.46 9.40
P/B 3.90 0.61 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.54 0.66
EV/Sales 28.74 (1.49) 9.02
Earnings yield (87.99%) (86.62%) (32.88%)
Free cash flow yield (71.97%) (78.12%) (23.13%)

Profitability

Metric BCDA LPCN Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 0.00% (269.05%) 0.00%
Net margin 0.00% (249.16%) 0.00%
Free cash flow margin 0.00% (267.37%) 0.00%
Return on equity (1,803.19%) (52.86%) (51.96%)
Return on assets (214.47%) (47.52%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCDA LPCN Biotechnology median
Revenue growth (TTM) 0.71% (13.36%) 6.76%
EPS growth (last fiscal year) 57.59% (93,988.89%) 29.88%
Revenue growth, 5-year CAGR 26.89% 64.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCDA LPCN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.09 11.36 4.97
Net debt to EBITDA 0.30 1.42 1.01

Dividend

Metric BCDA LPCN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BCDA LPCN Biotechnology median
Market cap 13.47m 12.61m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack